CRISPR Therapeutics AG Common Shares Earnings Dividend
Earnings Summary
Revenue | $10.18Mn |
Net Profits | $-91.15Mn |
Net Profit Margins | -895.33% |
CRISPR Therapeutics AG Common Shares’s revenue jumped 1041.37% since last year same period to $10.18Mn in the Q2 2026. On a quarterly growth basis, CRISPR Therapeutics AG Common Shares has generated 598.29% jump in its revenue since last 3-months.
CRISPR Therapeutics AG Common Shares’s net profit jumped 56.29% since last year same period to $-91.15Mn in the Q2 2026. On a quarterly growth basis, CRISPR Therapeutics AG Common Shares has generated 25.85% jump in its net profits since last 3-months.
CRISPR Therapeutics AG Common Shares’s net profit margin jumped 96.17% since last year same period to -895.33% in the Q2 2026. On a quarterly growth basis, CRISPR Therapeutics AG Common Shares has generated 89.38% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.1 |
EPS Estimate Current Year | -1.1 |
CRISPR Therapeutics AG Common Shares’s earning per share (EPS) estimates for the current quarter stand at -1.1 - a 10.57% jump from last quarter’s estimates.
CRISPR Therapeutics AG Common Shares’s earning per share (EPS) estimates for the current year stand at -1.1.
Key Ratios
Earning Per Share (EPS) | -0.94 |
CRISPR Therapeutics AG Common Shares’s earning per share (EPS) jumped 27.13% since last year same period to -0.94 in the Q2 2026. This indicates that the CRISPR Therapeutics AG Common Shares has generated 27.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-03 | -1.1 | -0.94 | 14.55% |
2026-05-04 | -1.23 | -1.28 | -4.07% |
